Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
March 13, 2024 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
March 12, 2024 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
March 06, 2024 16:25 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
February 29, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience,...
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
February 07, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
January 03, 2024 16:30 ET
|
Vigil Neuroscience, Inc.
- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected...
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
November 22, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
November 16, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent...
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small...
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
October 17, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...